rehmannic acid profile

rehmannic acid: toxic principle, triterpene acid from Lantana camara; RN given refers to (22beta-(Z))-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Flora	Rank	Flora Definition	Family	Family Definition
Lantana	genus	A plant genus of the family VERBENACEAE. Members contain lantadene and other TRITERPENES.[MeSH]	Verbenaceae	A plant family of the order Lamiales, subclass Asteridae, class Magnoliopsida. The leaves are opposite or whorled. The flowers are aggregated in spikes, clusters, or racemes.[MeSH]

ID Source	ID
PubMed CID	6436598
CHEMBL ID	510691
MeSH ID	M0071206

Synonym
22-beta-angeloyloxyoleanolic acid
22-((2-methyl-1-oxo-2-butenyl)oxy)-3-oxo-olean-12-en-28-oic acid, 22-beta(z)-
rehmannic acid
olean-12-en-28-oic acid, 22-((2-methyl-1-oxo-2-butenyl)oxy)-3-oxo-, (22beta(z))-
lantadene a
olean-12-en-28-oic acid, 22beta-hydroxy-3-oxo-, 2-methylcrotonate, (z)-
olean-12-en-28-oic acid, 22-beta-hydroxy-3-oxo-, 2-methylcrotonate, (z)-
hsdb 3503
22-((2-methyl-1-oxo-2-butenyl)oxy)-3-oxo-olean-12-en-28-oic acid, (22beta)
CHEMBL510691
467-81-2
unii-9sk62wcu1w
9sk62wcu1w ,
olean-12-en-28-oic acid, 22-(((2z)-2-methyl-1-oxo-2-buten-1-yl)oxy)-3-oxo-, (22.beta.)-
FS-9303
Q27273075
(22beta)-22-[[(2z)-2-methyl-1-oxo-2-buten-1-yl]oxy]-3-oxoolean-12-en-28-oic acid
DTXSID401139272
CS-0017064
HY-N1521
rehmannicacid
AKOS040762278

Excerpt	Reference	Relevance
"Liver injury occurred after sheep were injected intravenously with the triperpene acid lantadene A, the toxic principle of the tropical plant Lantana camara."	( Lantadene A toxicity in sheep. A model for cholestasis. Heath, TJ; Lamberton, JA; Pass, MA; Seawright, AA, 1979)	0.26

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)	IC50 (µMol)	1.0600	0.0001	1.9731	8.0000	AID1183838
Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)	IC50 (µMol)	1.0600	0.0001	1.8088	8.0000	AID1183838
Transcription factor p65	Homo sapiens (human)	IC50 (µMol)	1.0600	0.0001	1.8981	8.8000	AID1183838
Bcl-2-like protein 1	Homo sapiens (human)	Ki	100.0000	0.0000	0.4581	9.0000	AID426714
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of transcription by RNA polymerase II	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to lipopolysaccharide	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
transcription by RNA polymerase II	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
apoptotic process	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
inflammatory response	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
canonical NF-kappaB signal transduction	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
JNK cascade	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of gene expression	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of lipid storage	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of calcidiol 1-monooxygenase activity	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of vitamin D biosynthetic process	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of cholesterol transport	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of interleukin-12 production	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
response to muscle stretch	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
non-canonical NF-kappaB signal transduction	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of apoptotic process	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of DNA-templated transcription	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of inflammatory response	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
B cell receptor signaling pathway	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of protein metabolic process	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
mammary gland involution	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of transcription initiation by RNA polymerase II	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to mechanical stimulus	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to nicotine	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to interleukin-1	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to interleukin-6	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to tumor necrosis factor	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to dsRNA	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to interleukin-17	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to virus	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
antibacterial innate immune response	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of hyaluronan biosynthetic process	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to angiotensin	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of miRNA metabolic process	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to stress	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
innate immune response	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
response to cytokine	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
follicular dendritic cell differentiation	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
germinal center formation	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
regulation of DNA-templated transcription	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
canonical NF-kappaB signal transduction	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
extracellular matrix organization	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
response to lipopolysaccharide	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
rhythmic process	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
spleen development	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
cellular response to stress	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
innate immune response	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
non-canonical NF-kappaB signal transduction	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
response to cytokine	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
inflammatory response	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
positive regulation of interleukin-1 beta production	Transcription factor p65	Homo sapiens (human)
positive regulation of interleukin-6 production	Transcription factor p65	Homo sapiens (human)
positive regulation of interleukin-8 production	Transcription factor p65	Homo sapiens (human)
positive regulation of amyloid-beta formation	Transcription factor p65	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Transcription factor p65	Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathway	Transcription factor p65	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Transcription factor p65	Homo sapiens (human)
liver development	Transcription factor p65	Homo sapiens (human)
hair follicle development	Transcription factor p65	Homo sapiens (human)
defense response to tumor cell	Transcription factor p65	Homo sapiens (human)
response to ischemia	Transcription factor p65	Homo sapiens (human)
acetaldehyde metabolic process	Transcription factor p65	Homo sapiens (human)
chromatin organization	Transcription factor p65	Homo sapiens (human)
DNA-templated transcription	Transcription factor p65	Homo sapiens (human)
regulation of DNA-templated transcription	Transcription factor p65	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Transcription factor p65	Homo sapiens (human)
inflammatory response	Transcription factor p65	Homo sapiens (human)
cellular defense response	Transcription factor p65	Homo sapiens (human)
neuropeptide signaling pathway	Transcription factor p65	Homo sapiens (human)
canonical NF-kappaB signal transduction	Transcription factor p65	Homo sapiens (human)
positive regulation of cell population proliferation	Transcription factor p65	Homo sapiens (human)
response to xenobiotic stimulus	Transcription factor p65	Homo sapiens (human)
animal organ morphogenesis	Transcription factor p65	Homo sapiens (human)
response to UV-B	Transcription factor p65	Homo sapiens (human)
positive regulation of vascular endothelial growth factor production	Transcription factor p65	Homo sapiens (human)
positive regulation of gene expression	Transcription factor p65	Homo sapiens (human)
positive regulation of Schwann cell differentiation	Transcription factor p65	Homo sapiens (human)
negative regulation of angiogenesis	Transcription factor p65	Homo sapiens (human)
cytokine-mediated signaling pathway	Transcription factor p65	Homo sapiens (human)
protein catabolic process	Transcription factor p65	Homo sapiens (human)
response to muramyl dipeptide	Transcription factor p65	Homo sapiens (human)
response to progesterone	Transcription factor p65	Homo sapiens (human)
positive regulation of interleukin-12 production	Transcription factor p65	Homo sapiens (human)
positive regulation of interleukin-6 production	Transcription factor p65	Homo sapiens (human)
positive regulation of interleukin-8 production	Transcription factor p65	Homo sapiens (human)
response to insulin	Transcription factor p65	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Transcription factor p65	Homo sapiens (human)
negative regulation of protein sumoylation	Transcription factor p65	Homo sapiens (human)
response to cobalamin	Transcription factor p65	Homo sapiens (human)
toll-like receptor 4 signaling pathway	Transcription factor p65	Homo sapiens (human)
intracellular signal transduction	Transcription factor p65	Homo sapiens (human)
cellular response to hepatocyte growth factor stimulus	Transcription factor p65	Homo sapiens (human)
response to muscle stretch	Transcription factor p65	Homo sapiens (human)
non-canonical NF-kappaB signal transduction	Transcription factor p65	Homo sapiens (human)
vascular endothelial growth factor signaling pathway	Transcription factor p65	Homo sapiens (human)
prolactin signaling pathway	Transcription factor p65	Homo sapiens (human)
negative regulation of protein catabolic process	Transcription factor p65	Homo sapiens (human)
negative regulation of apoptotic process	Transcription factor p65	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Transcription factor p65	Homo sapiens (human)
response to amino acid	Transcription factor p65	Homo sapiens (human)
negative regulation of DNA-templated transcription	Transcription factor p65	Homo sapiens (human)
positive regulation of DNA-templated transcription	Transcription factor p65	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Transcription factor p65	Homo sapiens (human)
negative regulation of insulin receptor signaling pathway	Transcription factor p65	Homo sapiens (human)
regulation of inflammatory response	Transcription factor p65	Homo sapiens (human)
positive regulation of T cell receptor signaling pathway	Transcription factor p65	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Transcription factor p65	Homo sapiens (human)
response to cAMP	Transcription factor p65	Homo sapiens (human)
defense response to virus	Transcription factor p65	Homo sapiens (human)
cellular response to hydrogen peroxide	Transcription factor p65	Homo sapiens (human)
interleukin-1-mediated signaling pathway	Transcription factor p65	Homo sapiens (human)
response to interleukin-1	Transcription factor p65	Homo sapiens (human)
cellular response to lipopolysaccharide	Transcription factor p65	Homo sapiens (human)
cellular response to lipoteichoic acid	Transcription factor p65	Homo sapiens (human)
cellular response to peptidoglycan	Transcription factor p65	Homo sapiens (human)
cellular response to nicotine	Transcription factor p65	Homo sapiens (human)
cellular response to interleukin-1	Transcription factor p65	Homo sapiens (human)
cellular response to interleukin-6	Transcription factor p65	Homo sapiens (human)
cellular response to tumor necrosis factor	Transcription factor p65	Homo sapiens (human)
postsynapse to nucleus signaling pathway	Transcription factor p65	Homo sapiens (human)
antiviral innate immune response	Transcription factor p65	Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transduction	Transcription factor p65	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Transcription factor p65	Homo sapiens (human)
negative regulation of miRNA transcription	Transcription factor p65	Homo sapiens (human)
positive regulation of miRNA transcription	Transcription factor p65	Homo sapiens (human)
cellular response to angiotensin	Transcription factor p65	Homo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cell	Transcription factor p65	Homo sapiens (human)
positive regulation of miRNA metabolic process	Transcription factor p65	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway	Transcription factor p65	Homo sapiens (human)
cellular response to stress	Transcription factor p65	Homo sapiens (human)
response to cytokine	Transcription factor p65	Homo sapiens (human)
innate immune response	Transcription factor p65	Homo sapiens (human)
response to cytokine	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of apoptotic process	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptors	Bcl-2-like protein 1	Homo sapiens (human)
ovarian follicle development	Bcl-2-like protein 1	Homo sapiens (human)
in utero embryonic development	Bcl-2-like protein 1	Homo sapiens (human)
release of cytochrome c from mitochondria	Bcl-2-like protein 1	Homo sapiens (human)
endocytosis	Bcl-2-like protein 1	Homo sapiens (human)
germ cell development	Bcl-2-like protein 1	Homo sapiens (human)
spermatogenesis	Bcl-2-like protein 1	Homo sapiens (human)
male gonad development	Bcl-2-like protein 1	Homo sapiens (human)
apoptotic mitochondrial changes	Bcl-2-like protein 1	Homo sapiens (human)
fertilization	Bcl-2-like protein 1	Homo sapiens (human)
regulation of cytokinesis	Bcl-2-like protein 1	Homo sapiens (human)
positive regulation of mononuclear cell proliferation	Bcl-2-like protein 1	Homo sapiens (human)
ectopic germ cell programmed cell death	Bcl-2-like protein 1	Homo sapiens (human)
regulation of growth	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of apoptotic process	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of neuron apoptotic process	Bcl-2-like protein 1	Homo sapiens (human)
dendritic cell proliferation	Bcl-2-like protein 1	Homo sapiens (human)
response to cycloheximide	Bcl-2-like protein 1	Homo sapiens (human)
regulation of mitochondrial membrane permeability	Bcl-2-like protein 1	Homo sapiens (human)
epithelial cell proliferation	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of developmental process	Bcl-2-like protein 1	Homo sapiens (human)
neuron apoptotic process	Bcl-2-like protein 1	Homo sapiens (human)
defense response to virus	Bcl-2-like protein 1	Homo sapiens (human)
regulation of mitochondrial membrane potential	Bcl-2-like protein 1	Homo sapiens (human)
cellular response to amino acid stimulus	Bcl-2-like protein 1	Homo sapiens (human)
cellular response to alkaloid	Bcl-2-like protein 1	Homo sapiens (human)
cellular response to gamma radiation	Bcl-2-like protein 1	Homo sapiens (human)
apoptotic process in bone marrow cell	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of release of cytochrome c from mitochondria	Bcl-2-like protein 1	Homo sapiens (human)
dendritic cell apoptotic process	Bcl-2-like protein 1	Homo sapiens (human)
hepatocyte apoptotic process	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of execution phase of apoptosis	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of protein localization to plasma membrane	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of reproductive process	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of dendritic cell apoptotic process	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand	Bcl-2-like protein 1	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway	Bcl-2-like protein 1	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage	Bcl-2-like protein 1	Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligand	Bcl-2-like protein 1	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Bcl-2-like protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
transcription cis-regulatory region binding	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
chromatin binding	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
DNA-binding transcription factor activity	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
transcription coregulator activity	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
protein binding	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
identical protein binding	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
actinin binding	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
DNA-binding transcription factor activity	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
protein binding	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
transcription cis-regulatory region binding	Transcription factor p65	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Transcription factor p65	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Transcription factor p65	Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA binding	Transcription factor p65	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Transcription factor p65	Homo sapiens (human)
transcription coactivator binding	Transcription factor p65	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Transcription factor p65	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Transcription factor p65	Homo sapiens (human)
DNA binding	Transcription factor p65	Homo sapiens (human)
chromatin binding	Transcription factor p65	Homo sapiens (human)
DNA-binding transcription factor activity	Transcription factor p65	Homo sapiens (human)
protein binding	Transcription factor p65	Homo sapiens (human)
enzyme binding	Transcription factor p65	Homo sapiens (human)
protein kinase binding	Transcription factor p65	Homo sapiens (human)
chromatin DNA binding	Transcription factor p65	Homo sapiens (human)
ubiquitin protein ligase binding	Transcription factor p65	Homo sapiens (human)
peptide binding	Transcription factor p65	Homo sapiens (human)
phosphate ion binding	Transcription factor p65	Homo sapiens (human)
identical protein binding	Transcription factor p65	Homo sapiens (human)
protein homodimerization activity	Transcription factor p65	Homo sapiens (human)
actinin binding	Transcription factor p65	Homo sapiens (human)
histone deacetylase binding	Transcription factor p65	Homo sapiens (human)
NF-kappaB binding	Transcription factor p65	Homo sapiens (human)
ankyrin repeat binding	Transcription factor p65	Homo sapiens (human)
general transcription initiation factor binding	Transcription factor p65	Homo sapiens (human)
DNA-binding transcription factor binding	Transcription factor p65	Homo sapiens (human)
protein binding	Bcl-2-like protein 1	Homo sapiens (human)
protein kinase binding	Bcl-2-like protein 1	Homo sapiens (human)
identical protein binding	Bcl-2-like protein 1	Homo sapiens (human)
BH3 domain binding	Bcl-2-like protein 1	Homo sapiens (human)
BH domain binding	Bcl-2-like protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular region	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
nucleus	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
nucleoplasm	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cytoplasm	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
mitochondrion	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cytosol	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
secretory granule lumen	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
specific granule lumen	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
chromatin	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
transcription regulator complex	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
I-kappaB/NF-kappaB complex	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
nucleus	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cytoplasm	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
NF-kappaB p50/p65 complex	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
nucleus	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
nucleoplasm	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
cytoplasm	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
cytosol	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
chromatin	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
Bcl3/NF-kappaB2 complex	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
cytoplasm	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
nucleus	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
nucleolus	Transcription factor p65	Homo sapiens (human)
nucleus	Transcription factor p65	Homo sapiens (human)
glutamatergic synapse	Transcription factor p65	Homo sapiens (human)
nucleus	Transcription factor p65	Homo sapiens (human)
nucleoplasm	Transcription factor p65	Homo sapiens (human)
cytoplasm	Transcription factor p65	Homo sapiens (human)
cytosol	Transcription factor p65	Homo sapiens (human)
NF-kappaB p50/p65 complex	Transcription factor p65	Homo sapiens (human)
NF-kappaB complex	Transcription factor p65	Homo sapiens (human)
chromatin	Transcription factor p65	Homo sapiens (human)
transcription regulator complex	Transcription factor p65	Homo sapiens (human)
cytoplasm	Transcription factor p65	Homo sapiens (human)
cytoplasm	Bcl-2-like protein 1	Homo sapiens (human)
mitochondrion	Bcl-2-like protein 1	Homo sapiens (human)
mitochondrial outer membrane	Bcl-2-like protein 1	Homo sapiens (human)
mitochondrial inner membrane	Bcl-2-like protein 1	Homo sapiens (human)
mitochondrial matrix	Bcl-2-like protein 1	Homo sapiens (human)
endoplasmic reticulum	Bcl-2-like protein 1	Homo sapiens (human)
centrosome	Bcl-2-like protein 1	Homo sapiens (human)
cytosol	Bcl-2-like protein 1	Homo sapiens (human)
synaptic vesicle membrane	Bcl-2-like protein 1	Homo sapiens (human)
nuclear membrane	Bcl-2-like protein 1	Homo sapiens (human)
Bcl-2 family protein complex	Bcl-2-like protein 1	Homo sapiens (human)
mitochondrial outer membrane	Bcl-2-like protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (432)

Assay ID	Title	Year	Journal	Article
AID763356	Growth inhibition of human HT-29 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763388	Growth inhibition of human CAKI-1 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763190	Growth inhibition of human MOLT4 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763256	Growth inhibition of human T47D cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763220	Growth inhibition of human SK-MEL-5 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763340	Growth inhibition of human UACC257 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763156	Growth inhibition of human OVCAR5 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763182	Growth inhibition of human NCI-H460 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763327	Growth inhibition of human RXF393 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763142	Growth inhibition of human MCF7 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763354	Growth inhibition of human SW620 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763244	Growth inhibition of human NCI-H226 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763369	Growth inhibition of human A549/ATCC cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763171	Growth inhibition of human SNB19 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763121	Growth inhibition of human HCT116 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763357	Growth inhibition of human HCT15 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763170	Growth inhibition of human SF539 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763179	Growth inhibition of human HCC2998 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763314	Growth inhibition of human CCRF-CEM cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763169	Growth inhibition of human SNB75 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763233	Growth inhibition of human SW620 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763167	Growth inhibition of human LOXIMVI cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763150	Growth inhibition of human A498 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763257	Growth inhibition of human BT549 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763166	Growth inhibition of human MALME-3M cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763504	Growth inhibition of human RXF393 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763472	Growth inhibition of human SF268 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763188	Growth inhibition of human A549/ATCC cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763246	Growth inhibition of human HOP62 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763141	Growth inhibition of human MDA-MB-231 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763146	Growth inhibition of human TK10 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID1183838	Inhibition of TNFalpha-induced NF-kappaB activation in human A549 cells after 7 hrs by luciferase reporter gene assay	2014	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16	Synthesis of lantadene analogs with marked in vitro inhibition of lung adenocarcinoma and TNF-α induced nuclear factor-kappa B (NF-κB) activation.
AID763157	Growth inhibition of human OVCAR4 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763155	Growth inhibition of human OVCAR8 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763205	Growth inhibition of human SN12C cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763112	Growth inhibition of human SNB19 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763163	Growth inhibition of human SK-MEL-28 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763168	Growth inhibition of human U251 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID426713	Cytotoxicity against mouse L1210 cells	2009	Journal of natural products, Jul, Volume: 72, Issue:7	Cytotoxic pentacyclic triterpenoids from Combretum sundaicum and Lantana camara as inhibitors of Bcl-xL/BakBH3 domain peptide interaction.
AID763304	Growth inhibition of human NCI-H226 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763145	Growth inhibition of human UO31 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763226	Growth inhibition of human MALME-3M cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763212	Growth inhibition of human NCI-ADR-RES cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763373	Growth inhibition of human HL-60(TB) cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763308	Growth inhibition of human A549/ATCC cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763317	Growth inhibition of human T47D cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763137	Growth inhibition of human MDA-MB-468 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763185	Growth inhibition of human NCI-H226 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763492	Growth inhibition of human MDA-MB-468 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763391	Growth inhibition of human SKOV3 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763154	Growth inhibition of human NCI-ADR-RES cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763161	Growth inhibition of human UACC257 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763187	Growth inhibition of human HOP92 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID344231	Cytotoxicity against human colon 502713 cells after 48 hrs by MTT assay	2008	Journal of natural products, Jul, Volume: 71, Issue:7	Lantadenes and their esters as potential antitumor agents.
AID763439	Growth inhibition of human DU145 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763115	Growth inhibition of human SF268 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763139	Growth inhibition of human BT549 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763267	Growth inhibition of human CAKI-1 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763270	Growth inhibition of human 786-0 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763111	Growth inhibition of human SNB75 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763318	Growth inhibition of human BT549 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763194	Growth inhibition of human CCRF-CEM cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763172	Growth inhibition of human SF295 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763265	Growth inhibition of human SN12C cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763306	Growth inhibition of human EKVX cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763497	Growth inhibition of human MDA-MB-231 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763189	Growth inhibition of human SR cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763160	Growth inhibition of human IGROV1 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763249	Growth inhibition of human SR cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763191	Growth inhibition of human RPMI8226 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763219	Growth inhibition of human UACC257 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763444	Growth inhibition of human SN12C cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763473	Growth inhibition of human KM12 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763331	Growth inhibition of human 786-0 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763138	Growth inhibition of human T47D cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763386	Growth inhibition of human RXF393 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763241	Growth inhibition of human NCI-H460 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763385	Growth inhibition of human TK10 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763174	Growth inhibition of human SW620 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763479	Growth inhibition of human NCI-H460 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763364	Growth inhibition of human NCI-H23 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763339	Growth inhibition of human UACC62 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763162	Growth inhibition of human SK-MEL-5 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763140	Growth inhibition of human Hs 578T cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763261	Growth inhibition of human DU145 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763176	Growth inhibition of human HT-29 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763153	Growth inhibition of human SKOV3 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID426711	Cytotoxicity against human HCT116 cells	2009	Journal of natural products, Jul, Volume: 72, Issue:7	Cytotoxic pentacyclic triterpenoids from Combretum sundaicum and Lantana camara as inhibitors of Bcl-xL/BakBH3 domain peptide interaction.
AID763315	Growth inhibition of human SK-MEL-2 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763418	Growth inhibition of human HCC2998 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763277	Growth inhibition of human IGROV1 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763278	Growth inhibition of human UACC257 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763367	Growth inhibition of human HOP92 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763250	Growth inhibition of human RPMI8226 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763382	Growth inhibition of human DU145 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763484	Growth inhibition of human NCI-H226 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763118	Growth inhibition of human HT-29 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763193	Growth inhibition of human HL-60(TB) cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763493	Growth inhibition of human CCRF-CEM cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763120	Growth inhibition of human HCC2998 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763103	Growth inhibition of human SK-MEL-5 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763338	Growth inhibition of human IGROV1 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763184	Growth inhibition of human NCI-H23 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763225	Growth inhibition of human LOXIMVI cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID358519	Cytotoxicity against african green monkey Vero cells	2001	Journal of natural products, Jan, Volume: 64, Issue:1	Antitubercular activity of triterpenoids from Lippia turbinata.
AID763126	Growth inhibition of human NCI-H23 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763365	Growth inhibition of human NCI-H226 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763393	Growth inhibition of human OVCAR5 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763334	Growth inhibition of human OVCAR8 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763360	Growth inhibition of human HCC2998 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763455	Growth inhibition of human OVCAR3 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763213	Growth inhibition of human OVCAR8 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763434	Growth inhibition of human CCRF-CEM cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID344230	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	2008	Journal of natural products, Jul, Volume: 71, Issue:7	Lantadenes and their esters as potential antitumor agents.
AID763426	Growth inhibition of human HOP62 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763510	Growth inhibition of human OVCAR8 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763341	Growth inhibition of human SK-MEL-5 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763151	Growth inhibition of human ACHN cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763147	Growth inhibition of human SN12C cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763099	Growth inhibition of human OVCAR3 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763351	Growth inhibition of human SF539 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763175	Growth inhibition of human KM12 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763300	Growth inhibition of human NCI-H522 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763183	Growth inhibition of human NCI-H322M cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763200	Growth inhibition of human MCF7 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763417	Growth inhibition of human HCT116 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763165	Growth inhibition of human M14 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763414	Growth inhibition of human KM12 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763173	Growth inhibition of human SF268 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763285	Growth inhibition of human MALME-3M cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763186	Growth inhibition of human HOP62 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763404	Growth inhibition of human M14 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763407	Growth inhibition of human U251 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763438	Growth inhibition of human MDA-MB-231 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763397	Growth inhibition of human OVCAR3 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763362	Growth inhibition of human NCI-H522 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID426714	Binding affinity to Bcl-xL by fluorescein-labeled Bak-BH3 peptide competition binding assay	2009	Journal of natural products, Jul, Volume: 72, Issue:7	Cytotoxic pentacyclic triterpenoids from Combretum sundaicum and Lantana camara as inhibitors of Bcl-xL/BakBH3 domain peptide interaction.
AID763180	Growth inhibition of human COLO205 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763238	Growth inhibition of human HCC2998 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763128	Growth inhibition of human HOP92 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763328	Growth inhibition of human CAKI-1 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID1069865	Inhibition of TNF-alpha-induced NF-kappaB (unknown origin) activation transfected in human A549 cells after 7 hrs by bright-glo luciferase reporter gene assay	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Novel lung adenocarcinoma and nuclear factor-kappa B (NF-κB) inhibitors: synthesis and evaluation of lantadene congeners.
AID763384	Growth inhibition of human SN12C cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763117	Growth inhibition of human KM12 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763125	Growth inhibition of human NCI-H322M cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763416	Growth inhibition of human HCT15 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763247	Growth inhibition of human EKVX cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763144	Growth inhibition of human DU145 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763368	Growth inhibition of human SR cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763269	Growth inhibition of human A498 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763320	Growth inhibition of human MDA-MB-231 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763149	Growth inhibition of human CAKI-1 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763131	Growth inhibition of human SR cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763370	Growth inhibition of human RPMI8226 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763159	Growth inhibition of human UACC62 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763512	Growth inhibition of human OVCAR5 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763164	Growth inhibition of human MDA-MB-435 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763303	Growth inhibition of human NCI-H23 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763509	Growth inhibition of human SKOV3 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763148	Growth inhibition of human RXF393 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763252	Growth inhibition of human K562 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763251	Growth inhibition of human MOLT4 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763114	Growth inhibition of human SF539 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763198	Growth inhibition of human Hs 578T cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763430	Growth inhibition of human RPMI8226 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763130	Growth inhibition of human A549/ATCC cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID358518	Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 by radiometric BACTEC 460 system	2001	Journal of natural products, Jan, Volume: 64, Issue:1	Antitubercular activity of triterpenoids from Lippia turbinata.
AID763502	Growth inhibition of human TK10 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763395	Growth inhibition of human OVCAR4 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763335	Growth inhibition of human OVCAR5 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763218	Growth inhibition of human UACC62 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763451	Growth inhibition of human NCI-ADR-RES cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763177	Growth inhibition of human HCT116 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763429	Growth inhibition of human MOLT4 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763266	Growth inhibition of human RXF393 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763158	Growth inhibition of human OVCAR3 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763282	Growth inhibition of human SK-MEL-2 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763321	Growth inhibition of human MCF7 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763408	Growth inhibition of human SNB19 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763456	Growth inhibition of human IGROV1 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763104	Growth inhibition of human SK-MEL-28 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763333	Growth inhibition of human NCI-ADR-RES cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763110	Growth inhibition of human LOXIMVI cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763196	Growth inhibition of human T47D cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763431	Growth inhibition of human K562 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763398	Growth inhibition of human UACC62 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763295	Growth inhibition of human HT-29 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763260	Growth inhibition of human MCF7 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763366	Growth inhibition of human HOP62 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763281	Growth inhibition of human SK-MEL-28 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763332	Growth inhibition of human SKOV3 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763396	Growth inhibition of human IGROV1 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763253	Growth inhibition of human HL-60(TB) cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763322	Growth inhibition of human DU145 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763192	Growth inhibition of human K562 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763482	Growth inhibition of human NCI-H23 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763474	Growth inhibition of human HT-29 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763363	Growth inhibition of human NCI-H322M cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID426710	Cytotoxicity against human KB cells	2009	Journal of natural products, Jul, Volume: 72, Issue:7	Cytotoxic pentacyclic triterpenoids from Combretum sundaicum and Lantana camara as inhibitors of Bcl-xL/BakBH3 domain peptide interaction.
AID763221	Growth inhibition of human SK-MEL-2 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763448	Growth inhibition of human A498 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763222	Growth inhibition of human SK-MEL-28 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763350	Growth inhibition of human SNB19 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763403	Growth inhibition of human MDA-MB-435 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763309	Growth inhibition of human SR cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763237	Growth inhibition of human HCT116 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763143	Growth inhibition of human PC3 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763475	Growth inhibition of human HCT116 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763463	Growth inhibition of human M14 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763457	Growth inhibition of human UACC62 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763415	Growth inhibition of human HT-29 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763132	Growth inhibition of human RPMI8226 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763413	Growth inhibition of human SW620 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763441	Growth inhibition of human PC3 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763234	Growth inhibition of human KM12 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763276	Growth inhibition of human OVCAR3 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763263	Growth inhibition of human UO31 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763129	Growth inhibition of human HOP62 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763262	Growth inhibition of human PC3 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763505	Growth inhibition of human ACHN cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763450	Growth inhibition of human SKOV3 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763442	Growth inhibition of human TK10 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763470	Growth inhibition of human SF295 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763487	Growth inhibition of human A549/ATCC cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID344229	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	2008	Journal of natural products, Jul, Volume: 71, Issue:7	Lantadenes and their esters as potential antitumor agents.
AID763100	Growth inhibition of human IGROV1 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763204	Growth inhibition of human TK10 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763467	Growth inhibition of human SNB75 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763465	Growth inhibition of human LOXIMVI cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763294	Growth inhibition of human KM12 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763401	Growth inhibition of human SK-MEL-28 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763134	Growth inhibition of human MOLT4 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763460	Growth inhibition of human SK-MEL-28 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763422	Growth inhibition of human NCI-H322M cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763199	Growth inhibition of human MDA-MB-231 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763287	Growth inhibition of human U251 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763254	Growth inhibition of human CCRF-CEM cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763275	Growth inhibition of human OVCAR4 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763274	Growth inhibition of human OVCAR5 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763215	Growth inhibition of human OVCAR4 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763506	Growth inhibition of human CAKI-1 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763211	Growth inhibition of human SKOV3 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763443	Growth inhibition of human UO31 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763344	Growth inhibition of human MDA-MB-435 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763240	Growth inhibition of human NCI-H522 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763353	Growth inhibition of human SF295 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763449	Growth inhibition of human 786-0 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763389	Growth inhibition of human A498 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763394	Growth inhibition of human OVCAR8 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763181	Growth inhibition of human NCI-H522 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763231	Growth inhibition of human SF295 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763481	Growth inhibition of human NCI-H322M cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763283	Growth inhibition of human M14 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763376	Growth inhibition of human MDA-MB-468 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763280	Growth inhibition of human SK-MEL-5 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763122	Growth inhibition of human COLO205 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763379	Growth inhibition of human MDA-MB-231 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763273	Growth inhibition of human OVCAR8 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763206	Growth inhibition of human RXF393 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763383	Growth inhibition of human UO31 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763298	Growth inhibition of human HCC2998 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763501	Growth inhibition of human UO31 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763232	Growth inhibition of human SF268 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763466	Growth inhibition of human U251 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763133	Growth inhibition of human K562 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763264	Growth inhibition of human TK10 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763425	Growth inhibition of human HOP92 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763380	Growth inhibition of human MCF7 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763245	Growth inhibition of human HOP92 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763490	Growth inhibition of human MOLT4 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763288	Growth inhibition of human SNB75 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763372	Growth inhibition of human K562 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763109	Growth inhibition of human U251 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763440	Growth inhibition of human MCF7 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763123	Growth inhibition of human NCI-H460 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763358	Growth inhibition of human HCT116 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763310	Growth inhibition of human RPMI8226 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763286	Growth inhibition of human LOXIMVI cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763462	Growth inhibition of human SK-MEL-2 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763305	Growth inhibition of human HOP92 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763387	Growth inhibition of human ACHN cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763216	Growth inhibition of human OVCAR3 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763347	Growth inhibition of human U251 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763420	Growth inhibition of human NCI-H460 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763480	Growth inhibition of human NCI-H522 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763355	Growth inhibition of human KM12 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763284	Growth inhibition of human MDA-MB-435 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763135	Growth inhibition of human HL-60(TB) cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763313	Growth inhibition of human HL-60(TB) cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763223	Growth inhibition of human MDA-MB-435 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763235	Growth inhibition of human HT-29 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763259	Growth inhibition of human MDA-MB-231 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763311	Growth inhibition of human K562 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763428	Growth inhibition of human SR cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763513	Growth inhibition of human OVCAR4 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763390	Growth inhibition of human 786-0 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763346	Growth inhibition of human MALME-3M cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763435	Growth inhibition of human T47D cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763214	Growth inhibition of human OVCAR5 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763178	Growth inhibition of human HCT15 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763446	Growth inhibition of human RXF393 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763459	Growth inhibition of human UACC257 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763152	Growth inhibition of human 786-0 cells by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763500	Growth inhibition of human PC3 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763202	Growth inhibition of human PC3 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763424	Growth inhibition of human NCI-H23 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763447	Growth inhibition of human ACHN cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763272	Growth inhibition of human NCI-ADR-RES cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763195	Growth inhibition of human MDA-MB-468 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763461	Growth inhibition of human MDA-MB-435 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763228	Growth inhibition of human SNB75 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763239	Growth inhibition of human COLO205 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763279	Growth inhibition of human UACC62 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763496	Growth inhibition of human Hs 578T cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763483	Growth inhibition of human HOP92 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763476	Growth inhibition of human HCT15 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763323	Growth inhibition of human PC3 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID1069863	Cytotoxicity against human A549 cells after 48 hrs by MTT assay	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Novel lung adenocarcinoma and nuclear factor-kappa B (NF-κB) inhibitors: synthesis and evaluation of lantadene congeners.
AID763291	Growth inhibition of human SF295 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763292	Growth inhibition of human SF268 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763316	Growth inhibition of human MDA-MB-468 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763400	Growth inhibition of human UACC257 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763445	Growth inhibition of human CAKI-1 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763359	Growth inhibition of human COLO205 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763312	Growth inhibition of human MOLT4 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763498	Growth inhibition of human DU145 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763227	Growth inhibition of human U251 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763217	Growth inhibition of human IGROV1 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763348	Growth inhibition of human LOXIMVI cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763201	Growth inhibition of human DU145 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763107	Growth inhibition of human M14 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763342	Growth inhibition of human SK-MEL-2 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763258	Growth inhibition of human Hs 578T cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763326	Growth inhibition of human SN12C cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763268	Growth inhibition of human ACHN cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763478	Growth inhibition of human COLO205 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763330	Growth inhibition of human A498 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763503	Growth inhibition of human SN12C cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763511	Growth inhibition of human NCI-ADR-RES cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763102	Growth inhibition of human UACC62 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763119	Growth inhibition of human HCT15 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763229	Growth inhibition of human SNB19 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763488	Growth inhibition of human RPMI8226 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID1069866	Cytotoxicity against human A549 cells transfected with NF-kappaB assessed as reduction of cell viability relative to control	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Novel lung adenocarcinoma and nuclear factor-kappa B (NF-κB) inhibitors: synthesis and evaluation of lantadene congeners.
AID763127	Growth inhibition of human NCI-H226 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763243	Growth inhibition of human NCI-H23 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763392	Growth inhibition of human NCI-ADR-RES cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763464	Growth inhibition of human MALME-3M cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763352	Growth inhibition of human SF268 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763485	Growth inhibition of human HOP62 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763454	Growth inhibition of human OVCAR5 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763230	Growth inhibition of human SF539 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763271	Growth inhibition of human SKOV3 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763207	Growth inhibition of human CAKI-1 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID426712	Cytotoxicity against human MCF7 cells	2009	Journal of natural products, Jul, Volume: 72, Issue:7	Cytotoxic pentacyclic triterpenoids from Combretum sundaicum and Lantana camara as inhibitors of Bcl-xL/BakBH3 domain peptide interaction.
AID763421	Growth inhibition of human NCI-H522 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763378	Growth inhibition of human Hs 578T cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763486	Growth inhibition of human SR cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763101	Growth inhibition of human UACC257 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763361	Growth inhibition of human NCI-H460 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763491	Growth inhibition of human HL-60(TB) cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763337	Growth inhibition of human OVCAR4 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763336	Growth inhibition of human OVCAR3 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763319	Growth inhibition of human Hs 578T cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763402	Growth inhibition of human SK-MEL-2 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763405	Growth inhibition of human MALME-3M cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763494	Growth inhibition of human T47D cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763255	Growth inhibition of human MDA-MB-468 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763343	Growth inhibition of human SK-MEL-28 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763297	Growth inhibition of human HCT116 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763113	Growth inhibition of human SF295 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763197	Growth inhibition of human BT549 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763412	Growth inhibition of human SF295 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763410	Growth inhibition of human SF539 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763377	Growth inhibition of human BT549 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763293	Growth inhibition of human SW620 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763236	Growth inhibition of human HCT15 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763325	Growth inhibition of human TK10 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763136	Growth inhibition of human CCRF-CEM cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763495	Growth inhibition of human BT549 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763248	Growth inhibition of human A549/ATCC cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763411	Growth inhibition of human SF268 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763203	Growth inhibition of human UO31 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763105	Growth inhibition of human MDA-MB-435 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763307	Growth inhibition of human HOP62 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763427	Growth inhibition of human A549/ATCC cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763374	Growth inhibition of human CCRF-CEM cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763296	Growth inhibition of human HCT15 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763489	Growth inhibition of human K562 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763419	Growth inhibition of human COLO205 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763406	Growth inhibition of human LOXIMVI cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763371	Growth inhibition of human MOLT4 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763508	Growth inhibition of human A498 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763242	Growth inhibition of human NCI-H322M cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID344232	Cytotoxicity against human A549 cells after 48 hrs by MTT assay	2008	Journal of natural products, Jul, Volume: 71, Issue:7	Lantadenes and their esters as potential antitumor agents.
AID763224	Growth inhibition of human M14 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763423	Growth inhibition of human NCI-H226 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763432	Growth inhibition of human HL-60(TB) cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763499	Growth inhibition of human MCF7 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763108	Growth inhibition of human MALME-3M cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763437	Growth inhibition of human BT549 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763468	Growth inhibition of human SNB19 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763289	Growth inhibition of human SNB19 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763208	Growth inhibition of human ACHN cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763453	Growth inhibition of human OVCAR4 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763106	Growth inhibition of human SK-MEL-2 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763507	Growth inhibition of human 786-0 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763124	Growth inhibition of human NCI-H522 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763349	Growth inhibition of human SNB75 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763469	Growth inhibition of human SF539 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763477	Growth inhibition of human HCC2998 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID1183840	Cytotoxicity against human A549 cells after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16	Synthesis of lantadene analogs with marked in vitro inhibition of lung adenocarcinoma and TNF-α induced nuclear factor-kappa B (NF-κB) activation.
AID763209	Growth inhibition of human A498 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763302	Growth inhibition of human NCI-H322M cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID344233	Inhibition of DMBA-induced/TPA-promoted carcinogenesis in Swiss albino mouse squamous cells assessed as incidence of skin papillomas administered orally 1 week before DMPA administration and continued for 20 weeks relative to DMPA/TPA treated control	2008	Journal of natural products, Jul, Volume: 71, Issue:7	Lantadenes and their esters as potential antitumor agents.
AID763116	Growth inhibition of human SW620 cells assessed as cell growth at 10'-8 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763329	Growth inhibition of human ACHN cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763375	Growth inhibition of human T47D cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763458	Growth inhibition of human SK-MEL-5 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763471	Growth inhibition of human SW620 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763381	Growth inhibition of human PC3 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763324	Growth inhibition of human UO31 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763345	Growth inhibition of human M14 cells assessed as cell growth at 10'-4 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763301	Growth inhibition of human NCI-H460 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763210	Growth inhibition of human 786-0 cells assessed as growth inhibition at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763436	Growth inhibition of human Hs 578T cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763433	Growth inhibition of human MDA-MB-468 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763290	Growth inhibition of human SF539 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763299	Growth inhibition of human COLO205 cells assessed as cell growth at 10 uM by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763399	Growth inhibition of human SK-MEL-5 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763452	Growth inhibition of human OVCAR8 cells assessed as cell growth at 10'-7 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
AID763409	Growth inhibition of human SNB75 cells assessed as cell growth at 10'-6 M by sulforhodamine B assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	9 (27.27)	18.7374
1990's	5 (15.15)	18.2507
2000's	7 (21.21)	29.6817
2010's	11 (33.33)	24.3611
2020's	1 (3.03)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (2.86%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	34 (97.14%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	2.07	1	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
9,10-dimethyl-1,2-benzanthracene 9,10-Dimethyl-1,2-benzanthracene: Polycyclic aromatic hydrocarbon found in tobacco smoke that is a potent carcinogen.. 7,12-dimethyltetraphene : A tetraphene having methyl substituents at the 7- and 12-positions. It is a potent carcinogen and is present in tobacco smoke.	2.44	2	ortho-fused polycyclic arene; tetraphenes	carcinogenic agent
oleanolic acid [no description available]	5.8	29	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.04	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
docetaxel [no description available]	2.05	1	hydrate; secondary alpha-hydroxy ketone	antineoplastic agent
hydroxyl radical Hydroxyl Radical: The univalent radical OH. Hydroxyl radical is a potent oxidizing agent.	2.07	1	oxygen hydride; oxygen radical; reactive oxygen species
1,1-diphenyl-2-picrylhydrazyl 1,1-diphenyl-2-picrylhydrazyl: A diphenyl picrate; the ability to decolorize this stable radical indicates reactivity of tested compounds (Banda, Anal Chem 46:1772-7 1974)	2.07	1
bilirubin [no description available]	2.91	4	biladienes; dicarboxylic acid	antioxidant; human metabolite; mouse metabolite
acid phosphatase Acid Phosphatase: An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.2.	1.97	1
lantadene b lantadene B: RN given refers to the (22beta)-isomer; from Lantana camara	3.5	8
sapogenins Sapogenins: The aglucon moiety of a saponin molecule. It may be triterpenoid or steroid, usually spirostan, in nature.	3.21	6
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	2	1	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor

Condition	Relationship Strength	Studies
Adenocarcinoma, Basal Cell [description not available]	2.5	2
Cancer of Lung [description not available]	2.5	2
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.5	2
Lung Neoplasms Tumors or cancer of the LUNG.	2.5	2
Loa loa Filariasis [description not available]	2.17	1
Loiasis A parasitic infection caused by the nematode Loa loa. The vector in the transmission of this infection is the horsefly (Tabanus) or the deerfly or mango fly (Chrysops). The larvae may be seen just beneath the skin or passing through the conjunctiva. Eye lesions are not uncommon. The disease is generally mild and painless.	2.17	1
Onchocerciasis Infection with nematodes of the genus ONCHOCERCA. Characteristics include the presence of firm subcutaneous nodules filled with adult worms, PRURITUS, and ocular lesions.	2.17	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.08	1
Malignant Melanoma [description not available]	2.08	1
Cancer of Skin [description not available]	2.46	2
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	2.08	1
Skin Neoplasms Tumors or cancer of the SKIN.	2.46	2
Acute Liver Injury, Drug-Induced [description not available]	3.26	6
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	3.26	6
Carcinoma, Epidermoid [description not available]	2.06	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.06	1
Benign Neoplasms [description not available]	2.08	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.08	1
Experimental Neoplasms [description not available]	2.03	1
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	2.04	1
Papilloma, Squamous Cell [description not available]	2.04	1
Papilloma A circumscribed benign epithelial tumor projecting from the surrounding surface; more precisely, a benign epithelial neoplasm consisting of villous or arborescent outgrowths of fibrovascular stroma covered by neoplastic cells. (Stedman, 25th ed)	2.04	1
Bovine Diseases [description not available]	2.37	2
Extravascular Hemolysis [description not available]	1.96	1
Plant Poisoning Poisoning by the ingestion of plants or its leaves, berries, roots or stalks. The manifestations in both humans and animals vary in severity from mild to life threatening. In animals, especially domestic animals, it is usually the result of ingesting moldy or fermented forage.	3.57	3
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	1.96	1
Bile Duct Obstruction [description not available]	1.95	1
Liver Dysfunction [description not available]	1.95	1
Ovine Diseases [description not available]	2.37	2
Cholestasis Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).	1.95	1
Liver Diseases Pathological processes of the LIVER.	1.95	1
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	1.95	1

rehmannic acid

Description

Cross-References

Synonyms (22)

Research Excerpts

Toxicity

Protein Targets (4)

Inhibition Measurements

Biological Processes (147)

Molecular Functions (30)

Ceullar Components (24)

Bioassays (432)

Research

Studies (33)

Market Indicators

Research Demand Index: 11.03

Study Types

rehmannic acid

Description

Related Flora

Cross-References

Synonyms (22)

Research Excerpts

Toxicity

Protein Targets (4)

Inhibition Measurements

Biological Processes (147)

Molecular Functions (30)

Ceullar Components (24)

Bioassays (432)

Research

Studies (33)

Market Indicators

Research Demand Index: 11.03

Study Types

Related Drugs (12)

Related Conditions (32)